insulin glargine recombinant + therapeutic insulin
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperglycemia
Conditions
Hyperglycemia, Leukemia
Trial Timeline
May 1, 2009 → Mar 1, 2010
NCT ID
NCT00943709About insulin glargine recombinant + therapeutic insulin
insulin glargine recombinant + therapeutic insulin is a phase 3 stage product being developed by Sanofi for Hyperglycemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00943709. Target conditions include Hyperglycemia, Leukemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00943709 | Phase 3 | Withdrawn |
Competing Products
9 competing products in Hyperglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Exenatide + Insulin | Eli Lilly | Phase 2/3 | 65 |
| Human regular insulin + Insulin lispro + Insulin glargine | Eli Lilly | Phase 3 | 77 |
| Dapagliflozin + Sliding scale insulin | AstraZeneca | Approved | 85 |
| GLP-1 control + GLP-1 and Exendin(9-39) 300 + saline control + GLP-1 and Exendin(9-39) 600 + GLP-1 and Exendin(9-39) 900 + GLP-1 and Exendin(9-39) 1200 | Merck | Phase 1 | 33 |
| liraglutide + placebo | Novo Nordisk | Pre-clinical | 22 |
| Olanzapine + Ziprasidone | Pfizer | Pre-clinical | 22 |
| NPH insulin plus Complete Insulin Orders + Complete Insulin Orders | Sanofi | Approved | 84 |
| insulin glargine + insulin glargine + insulin glargine | Sanofi | Approved | 84 |
| Lantus® (insulin glargine) | Sanofi | Phase 1 | 32 |